Trial Profile
Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Daclizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 11 Aug 2015 New trial record